ArticleCancers2021

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.

Charlotte I Stroes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.